Company intelligence / Profile preview

CellmAbs

Óbidos, Leiria District, Portugalcellmabs.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Researchers at CellmAbs have developed a panel of novel humanized monoclonal antibodies with high specificity and affinity for glycan targets uniquely expressed on cancer cells. These candidates are in preclinical development for various solid tumor indications. The company recently signed a licensing agreement with BioNTech for one of its preclinical antibody candidates and ADC technology, which could yield significant milestone payments if successful.[1][3] No clinical results reported yet.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

8 assets

AMFA glycovectors

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

BioNTech (licensing agreement for an antibody candidate and ADC technology)[1]

Beyond the preview

Go deeper on CellmAbs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellmAbs.

Explore the full profile